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Abstract
Background: The Primary Breast Lymphomas (PBL) represent 0,38-0,70% of all non-Hodgkin lymphomas (NHL), 1,7-
2,2% of all extranodal NHL and only 0,04-0,5% of all breast cancer. Most frequent PBLs are the diffuse large B cell 
lymphomas; in any case-reports MALT lymphomas lack or are a rare occurrence. Their incidence is growing. From 1880 
(first breast resection for "lymphadenoid sarcoma" carried out by Gross) to the recent past the gold standard treatment 
for such diseases was surgery. At present such role has lost some of its importance, and it is matter of debate.
Methods: Twenty-three women affected by PBL underwent surgery. Average age was 63 years (range: 39-83). Seven 
suffered of hypothyroidism secondary to autoimmune thyroiditis. Fourteen patients underwent mastectomy, nine 
patients received quadrantectomy (average neoplasm diameter: 1,85 cm, range: 1,1-2,6 cm). In 10 cases axillary 
dissection was carried out. Pathologic examination revealed 16 diffuse large B cell lymphomas and 7 MALT lymphomas.
Results: Seven patients in the mastectomy group had a recurrence (50%), and all of them with diffuse large B cell 
lymphomas at stage II. Two of these had not received chemotherapy. No patient undergoing quadrantectomy had 
recurrence. In the mastectomy group disease free survival (DFS) at 5 and 10 years was 57 and 50%. Overall survival (OS) 
at 5 and 10 years was 71.4% and 57.1% respectively. All recurrences were systemic. DFS and OS at 5 and 10 years was 
100% in the quadrantectomy group. In the patients with recurrence mortality was 85.7%. For stage IE DFS and OS at 5 
and 10 years were 100%. For stage II DFS at 10 years was 62.5% and 56.2% respectively; OS at 5 and 10 years was 75% 
and 62.5% respectively. For MALT lymphomas DFS and OS at 5 and 10 years were 100%. For diffuse large B cell 
lymphomas DFS at 5 and 10 years was 62.5% and 56.2% respectively; OS at 5 and 10 years was 75% and 62,5% 
respectively.
Conclusions: The role of surgery in this disease should be limited to get a definitive diagnosis while for the staging and 
the treatment CT scan and chemio/radioterapy are repectively mandatory. MALT PBLs have a definitely better 
prognosis compared to large B cell lymphomas. The surgical treatment must always be oncologically radical (R0); 
mastectomy must not be carried out as a rule, but only when tissue sparing procedures are not feasible. Axillary 
dissection must always be performed for staging purposes, so avoiding the risk of under-staging II o IE, due to the 
possibility of clinically silent axillary node involvement.
Introduction
Non-Hodgkin lymphomas rarely affect the breast, the
majority being primary (~60%) [1]. Up to now, 700 Pri-
mary Breast Lymphomas (PBL) have been described as
case reports or case series [2-5]. PBLs generally affect
women (only 10 cases have been reported in men) [6-9].
Their incidence is growing; recently Aviles and coll. pre-
sented a review consisting of 96 patients [10], while the
International Extranodal Lymphoma Study Group
(IELSG) has registered 204 cases [11].
In the past, different criteria have been used to define
PBLs; presently the definition devised by Wiseman and
Liao [12], and modified by Hugh and coll. is the one gen-
erally accepted in the Literature [13]:* Correspondence: cirocchiroberto@yahoo.it
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present in close association in an adequate specimen;
• no evidence of widespread lymphoma by standard 
staging techniques or preceding extramammary lym-
phoma, although ipsilateral axillary node involvement 
is allowed if both lesions are present simultaneously.
From 1880 (first breast resection for "lymphadenoid
sarcoma" carried out by Gross) to the recent past the gold
standard treatment for such diseases was surgery [14]. At
present such role has lost some of its importance, and it is
matter of debate.
The endpoint of this study was to evaluate the role and
the benefits (DFS and OS) of surgical treatment in the
management of PLB.
Methods
From January 1993 to December 2003 23 women affected
by PBL underwent surgery. Average age was 63 years
(range: 39-83). Seven suffered of hypothyroidism second-
ary to autoimmune thyroiditis. Sixteen cases presented
with a palpable breast mass (11 on the right). Seven non-
palpable lesions were diagnosed at routine mammogra-
phy (5 on the right). In 1 case the mass infiltrated the
skin. Axillary lymphoadenomegaly was present in a 83-
year old patient. No patients complained of the typical
lymphoma-associated symptoms: fever, night sweats,
weight-loss. All patients were submitted to breast ultra-
sonography (US) and mammography; in 1 case a second
nodule was found in a different quadrant of the same
breast. FNAB, Core needle/Incision or excision biopsy of
breast lump were performed for confirmation before pro-
ceeding. Bone marrow biopsy and total-body CT scan-
ning were carried out on all patients. The diagnosis of
PBL was preoperatively for all cases.
Fourteen patients underwent mastectomy (median
neoplasm diameter: 5,5 cm, range: 3,5-8,7 cm) and 9
patients received quadrantectomy (median neoplasm
diameter: 1,85 cm, range: 1,1-2,6 cm). The operative deci-
sions (mastectomy vs quadrantectomy) were subordi-
nated to diameter of neoplasms.
The axillary dissection was performed only in 10
patients underwent mastectomy; the exception ware
patients presenting with clinically evident lymphoade-
nopathy and very elderly patients in not fit conditions.
Pathologic examination revealed 16 diffuse large B cell
lymphomas and 7 MALT lymphomas. Eleven of the
patients submitted to mastectomy had axillary node
involvement by the disease (stage II according to Ann
Arbor Classification).
No surgical complications were observed; in 6 case pro-
longed lymphatic drainage from the axillary dissection
site occurred.
All patients - except 3 elderly subjects in poor general
conditions (ASA III) - received systemic chemotherapy.
In 2 cases radiotherapy was added.
Results
Seven patients in the mastectomy group had a recurrence
(50%), and all of them with diffuse large B cell lymphomas
at stage II. Two of these had not received chemotherapy.
No patient undergoing quadrantectomy had recurrence.
In the mastectomy group disease free survival (DFS) at
5 and 10 years was 57 and 50%. Overall survival (OS) at 5
and 10 years was 71.4% and 57.1% respectively. All recur-
rences were systemic. DFS and OS at 5 and 10 years was
100% in the quadrantectomy group. In the patients with
recurrence mortality was 85.7%.
For stage IE DFS and OS at 5 and 10 years were 100%.
For stage II DFS at 10 years was 62.5% and 56.2% respec-
tively; OS at 5 and 10 years was 75% and 62.5% respec-
tively. For MALT lymphomas DFS and OS at 5 and 10
years were 100%. For diffuse large B cell lymphomas DFS
at 5 and 10 years was 62.5% and 56.2% respectively; OS at
5 and 10 years was 75% and 62,5% respectively.
Discussion
PBLs represent 0,38-0,70% of all non-Hodgkin lympho-
mas (NHL), 1,7-2,2% of all extranodal NHL [15-19]; and
only 0,04-0,5% of all breast cancer [16,18-23]. Most fre-
quent PBLs are diffuse large B cell lymphomas (53%) [4];
in any case-reports MALT lymphomas lack or are a rare
occurrence: 0 pts Bobrow [23], 0 pts Prévot [24], 4 pts
(44%) Mattia [16], 7 pts (20%) Hugh [13], 0 pts Jeon [25],
2 pts (5%) Arber [19], and 9 pts (64%) Farinha [26].
Burkitt-type PBLs are a relatively rare entity, typical of
young women.
Up to the recent past surgery was considered the gold
standard in the management of breast lymphomas
[22,27]. Presently such tenet has been challenged, and the
role of surgery has lost part of its importance [20].
Scientific societies have proposed guide-lines in order
to standardize therapeutic strategies. NCCN (National
Comprehensive Cancer Network) offers different solu-
tions based on histology and clinical stage according to
the Ann Arbor Classification [28,29]. For MALT lympho-
mas in stage IE and II there isn't a treatment of choice.
Surgery and Radiotherapy are equally effective in prog-
nostic terms. Surgery - of course - affords a better histo-
logical evaluation. For all large B cell lymphomas the
optimal treatment is chemotherapy. For MALT stage III
and IV the preferred therapy is chemo-and radiotherapy.
Furthermore, the ideal surgical technique is matter of
debate. Some Authors carry out routinely mastectomy
with axillary lymph-node dissection, others deem such
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ing resections (quadrantectomy, tumorectomy), always
associated with axillary lymph-node dissection and adju-
vant chemo- radiotherapy. Finally, some do not believe in
axillary dissection, so they don't perform it. In the review
from Jeanneret - Sozzi adjuvant chemotherapy showed
only scant advantages in terms of local control, and none
in terms of OS and DFS [30].
Disagreement regarding the treatment of such disease
stems from its rareness, with small case reports; conse-
quently, randomized controlled trials or clinically con-
trolled trials can not be carried out.
Jennings and coll. have recently published a review on
465 cases described in the Literature, and have showed
that mastectomy does not afford better results concern-
ing survival or recurrence [31]. More significant results
were reported by Jeanneret-Sozzi and coll. in a multi-
centric study on 84 patients treated from 1970 to 2000;
surgery is not a negative prognostic factor, on the con-
trary it turns out to be a positive prognostic index when-
ever a conservative procedure can be carried out [30].
Such evidence derives from the fact that - if technically
feasible - a limited resection of the neoplasm is sufficient
and that mastectomy is not able to change the outcome.
Statistically significative negative prognostic factors are:
tumor diameter (>4,5 cm) and lymphomatous dissemina-
tion to the axillary lymph-nodes [5].
Conclusion
The role of surgery in this disease should be limited to get
a definitive diagnosis while for the staging and the treat-
ment CT scan and chemio/radioterapy are respectively
mandatory. MALT PBLs have a definitely better progno-
sis compared to large B cell lymphomas. The surgical
treatment must always be oncologically radical (R0); mas-
tectomy must not be carried out as a rule, but only when
tissue sparing procedures are not feasible. Axillary dissec-
tion must always be performed for staging purposes, so
avoiding the risk of under-staging II o IE, due to the pos-
sibility of clinically silent axillary node involvement. Sur-
gical excision enables adequate pathologic evaluation, not
obtainable on FNA cytology, but provided by excisional
biopsy. Furthermore, surgery affords excellent local
tumor control, with clear advantages especially in elderly
patients with large neoplasms involving the skin. Nega-
tive prognostic factors are: tumor diameter, lymphoma-
tous dissemination to the axillary nodes.
The association between autoimmune thyroiditis and
breast lymphomas - that we observed in seven cases,
along with other Authors' reports - deserves to be investi-
gated in the close future.
Nowadays, surgical resection plays a therapeutic role
only in MALT lymphomas, whereas for large B cell lym-
phomas has only a diagnostic indication. For such dis-
ease, the cornerstone of treatment is systemic
chemotherapy.
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